

In the Claims:

Cancel claims 2-54.

Add the following new claims 55-71.

55. (New) A method for reducing coronary artery stenosis by at least 20% in a

Sub B1
mammal comprising the administration to said mammal of a combination of (a) a compound comprising eicosapentaenoic acid or docosahexaenoic acid and (b) a cholesterol synthesis or transfer inhibitor, in combination with limiting fat or cholesterol intake, whereby a serum LDL concentration of less than or equal to 70 mg/dl is achieved.

A2
56. (New) The method of claim 55, wherein said serum LDL concentration

achieved is less than 55 mg/dl.

57. (New) The method of claim 55, wherein said combination further comprises niacin.

58. (New) The method of claim 55, wherein said combination comprises aspirin.

Sub B2
59. (New) The method of claim 55, wherein said compound comprising eicosapentaenoic acid or docosahexaenoic acid is administered at greater than or equal to 5 g/day.

Sub B²

60. (New) The method of claim 55, wherein said compound is a marine lipid.

61. (New) The method of claim 60, wherein said marine lipid is a fish oil.

A 2

62. (New) The method of claim 55, wherein said cholesterol synthesis or transfer inhibitor is administered at greater than or equal to 10 mg/day.

63. (New) The method of claim 55, wherein said cholesterol synthesis or transfer inhibitor acts by inhibiting hydroxymethylglutarate (HMG) CoA reductase.

64. (New) The method of claim 55, wherein said cholesterol synthesis or transfer inhibitor is chosen from the group consisting of simvastatin, lovastatin, fluvastatin, and pravastatin.

65. (New) The method of claim 57, wherein said niacin is administered at between 0.5 - 3 g/day.

66. (New) The method of claim 58, wherein said aspirin is administered at greater than or equal to 80 mg/day.

67. (New) The method of claim 55, wherein said method further comprises administering to said mammal a bile acid sequestrant.

68. (New) The method of claim 67, wherein said sequestrant is administered at between 5 - 20 g/day.

AR

69. (New) The method of claim 67, wherein said sequestrant is chosen from cholestyramine or colestipol.

70. (New) The method of claim 55, wherein said method further comprises administering to said mammal buspirone.

71. (New) The method of claim 70, wherein said buspirone is administered at between 10 - 80 mg/day.

REMARKS

Claims 55-71 find support throughout the specification, for example, at page 3, line 22 - page 4, line 19.